Key events, in time order
Several independent X users note TMDX earnings reaction was overdone, business expanding, market opportunities exist
Management detailed 5-layer moat; slides to be posted on IR page
Beyond Q2 results, law firm probe, CEO 2032 target, and retail bottom-fishing comments add to the narrative
Two independent sources confirm, analyst warns of slower growth and potential Q2 miss
Company grants inducement awards under Nasdaq rule, law firm probes fiduciary breaches
Multiple independent analysts/traders highlight TMDX as a key earnings report this week
Q1 2026 total revenue was $174 million, representing 21% year-over-year growth and 8% sequential growth from Q4 2025
None yet
None yet
TransMedics Group ($TMDX) may be turning around after poor quarters, with strong Q3 flight averages suggesting surpassing Q2 revenues and beating estimates. Investors anticipate the next earnings call and FDA approval for CHOPS.
Main discussion
Different voices
After two abysmal quarters, maybe the tide is finally turning??? Possible additional catalysts for Q4: - $TMDX destroying Q3 estimates - $HOOD some more crypto volatility - $META getting some love https://t.co/BjbAzn456M
Can’t wait for $TMDX next earnings call. I wonder what’s taking so long for FDA to approve CHOPS, it’s not necessarily some new tech.
$TMDX continue to average over 30 flights a day in August. If they maintain that pace for the rest of Q3 they will likely surpass Q2 revenues. YoY growth would be over 35%. Way ahead of consensus.
𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -5.6% S&P500 YTD: +12.1% TOTAL RETURNS (Jan 2022) Natan's portfolio: +110.7% *Benchmark: +42.5% S&P500: +70.4% MY POSITIONS: 30.0% | Transmedics $TMDX 15.3% | Procept BioRobotics $PRCT 12.9% | Pinduoduo $PDD 11.4% | Robinhood $HOOD 10.0% | Meta Platfor
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
TransMedics makes a portable 'lung/heart/liver in a box' that keeps donor organs alive and monitored outside the body, extending their usable time for transplants. Think of it as an ICU on wheels for organs awaiting a recipient.
Revenue comes from selling and servicing the Organ Care System and its single-use perfusion modules. Gross margin is ~59%, with net income swinging from a loss in 2023 to USD 0.19B profit in 2025, indicating growing recurring consumable sales.
Regulatory approvals and clinical proof create a barrier, but competitors like XVIVO Perfusion and OrganOx are advancing rival organ-preservation devices. The moat is eroding as these alternatives gain traction and hospitals seek multiple suppliers.
Hold (sector percentile 37) — value B, growth C, profitability B, momentum C-, revisions B. Updated daily, sector-relative, identical for every user.
